Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Income from Continuing Operations of 48524000.0 for Q1 2026, up 65.63% sequentially from 141187000.0 in Q4 2025, and down 64.52% YoY from 136770532.87 in Q1 2025.
Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 48524000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 64.52% year-over-year to 48524000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 239488000.0 (down 441.44% YoY) and the FY2025 annual result came in at 220474000.0, down 1066.53% from the prior year.
- Income from Continuing Operations climbed to 48524000.0 in Q1 2026 per VNDA's latest filing, from 141187000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6861000.0 in Q4 2022 and troughed at 141187000.0 in Q4 2025.
- A 5-year average of 16420705.88 and a median of 4518000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 149.94% in 2023, then plunged 4000.73% in 2024.
- Over 5 years, Income from Continuing Operations stood at 6861000.0 in 2022, then plunged by 134.85% to 2391000.0 in 2023, then sank by 103.93% to 4876000.0 in 2024, then tumbled by 2795.55% to 141187000.0 in 2025, then jumped by 65.63% to 48524000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 48524000.0, 141187000.0, and 22590000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -62.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.51 Mn |
| Mar 31, 2026 | -48.52 Mn |
| Dec 31, 2025 | -141.19 Mn |
| Sep 30, 2025 | -22.59 Mn |
| Jun 30, 2025 | -27.19 Mn |
| Mar 31, 2025 | -29.49 Mn |
| Dec 31, 2024 | -4.88 Mn |
| Sep 30, 2024 | -5.34 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 6.86 Mn |
| Sep 30, 2022 | 3.26 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | -6.46 Mn |
| Dec 31, 2021 | 7.08 Mn |
| Sep 30, 2021 | 7.72 Mn |